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ABSTRACT
CpG islands (CGI) marked by bivalent chromatin in stem cells are believed 
to be more prone to aberrant DNA methylation in tumor cells. The robustness and 
genome-wide extent of this instructive program in different cancer types remain to be 
determined. To address this issue we developed a user-friendly approach to integrate 
the stem cell chromatin signature in customized DNA methylation analyses. We used 
publicly available ChIP-sequencing datasets of several human embryonic stem cell 
(hESC) lines to determine the extent of bivalent chromatin genome-wide. We then 
created annotated lists of high-confidence bivalent, H3K4me3-only and H3K27me3-
only chromatin regions. The main features of bivalent regions included localization 
in CGI/promoters, depletion in retroelements and enrichment in specific histone 
modifications, including the poorly characterized H3K23me2 mark. Moreover, bivalent 
promoters could be classified in three clusters based on PRC2 and PolII complexes 
occupancy. Genes with bivalent promoters of the PRC2-defined cluster displayed the 
lowest expression upon differentiation. As proof-of-concept, we assessed the DNA 
methylation pattern of eight types of tumors and confirmed that aberrant cancer-
associated DNA hypermethylation preferentially targets CGI characterized by bivalent 
chromatin in hESCs. We also found that such aberrant DNA hypermethylation affected 
particularly bivalent CGI/promoters associated with genes that tend to remain 
repressed upon differentiation. Strikingly, bivalent CGI were the most affected by 
aberrant DNA hypermethylation in both CpG Island Methylator Phenotype-positive 
(CIMP+) and CIMP-negative tumors, suggesting that, besides transcriptional silencing 
in the pre-tumorigenic cells, the bivalent chromatin signature in hESCs is a key 
determinant of the instructive program for aberrant DNA methylation.
INTRODUCTION
The proper development of higher organisms is a 
tightly regulated process in which epigenetic pathways 
are key determinants. Consistently, in addition to genetic 
lesions, epigenetic alterations are important actors in 
various human pathologies, including carcinogenesis. 
Specifically, aberrant DNA hypermethylation at gene 
promoter-associated CpG Islands (CGI/promoter) is a 
well characterized feature of cancer cells. In patients with 
glioma, colorectal or lung cancer, the CGI methylation 
pattern at some genes, such as MGMT [1], SEPT9 [2] or 
SHOX2 [3], can be used as a biomarker for diagnosis, 
prognosis or prediction of the response to therapies. 
Moreover, a CpG island methylator phenotype (CIMP), 
characterized by the concomitant hypermethylation 
of multiple CGIs, has been described in a subset of 
different tumor types [for review 4], including colorectal, 
gastric, breast and lung cancer as well as glioblastoma 
and hematological malignancies. Strikingly, CIMP-
positive tumors exhibit specific molecular features, 
clinical prognosis and outcome compared with CIMP-
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negative tumors [4], thus underlying the potential of these 
signatures as cancer biomarkers.
Studies on the molecular bases of CGI 
hypermethylation suggest the existence of an instructive 
program that relies on the CGI chromatin signature in stem 
cells. Specifically, both candidate-based and genome-wide 
analyses highlighted that genes marked in embryonic or 
adult stem cells by repressive polycomb group proteins 
(PcG) and more specifically by a bivalent chromatin 
signature are prone to be aberrantly methylated in cancer 
cells [5–8]. CGIs/Promoters with bivalent chromatin are 
concomitantly marked by the ‘active’ H3K4me3 and 
the ‘repressive’ H3K27me3 marks. Bivalent chromatin 
domains are thought to repress gene transcription through 
H3K27me3, while keeping genes ‘poised’ for alternative 
fates induced by specific developmental cues upon 
stem cell differentiation [9, 10]. Consistently, overlaps 
between the gene expression signatures of stem cells and 
aggressive tumors have been reported [11]. Altogether, 
these observations led to the hypothesis that besides 
mediating the stable silencing of tumor suppressor genes, 
the main consequence of CGI hypermethylation is to 
aberrantly maintain cancer cells in a “plastic” stem-cell 
like state (poor differentiation capacity and unlimited 
self-renewal) that contributes to cancer initiation and 
progression [5, 12, 13].  However, the observation that 
CIMP-positive tumors are associated with a better clinical 
prognosis [14, 15] challenged this hypothesis. Also, recent 
integrative genome-wide analyses revealed that aberrant 
CGI hypermethylation affects primarily genes that are 
already repressed in the matched normal tissue, indicating 
that most of the aberrantly methylated genes are not 
involved in carcinogenesis [8, 16, 17]. To account for these 
observations, Sproul and Meehan proposed an alternative 
hypothesis in which the stable repression brought by 
aberrant DNA hypermethylation at CGIs/promoters 
restricts the epigenetic plasticity of cancer cells and their 
ability to adapt following environmental changes, such as 
during metastasis formation or treatment, thus acting as 
a protective mechanism against cancer progression [18].
Evaluating if these two possibilities co-exist in 
cancer cells, with respect to cancer subtypes and/or 
stages of the disease, emerge thus as an important issue to 
formally characterize the role of DNA hypermethylation 
in tumors cells. For this, we need to precisely determine 
genome-wide to which extent the stem cell chromatin 
signature pre-marks CGIs for hypermethylation in 
cancer cells. DNA methylome studies in a variety of 
cancer cells have benefitted from the development of 
cost-effective and normalized tools, such as the Infinium 
HumanMethylation450 (HM450K) BeadChip Arrays 
or the recently released Infinium MethylationEPIC 
Arrays (both from Illumina) that allow comparing results 
between laboratories. However, the analysis of chromatin 
signatures in stem cells is hampered by the bioinformatics 
skills needed to handle the publicly available genome-
wide ChIP-sequencing datasets.
Alternatively, already processed lists of chromatin 
signatures could highly facilitate this kind of approach. 
Three initial studies have provided a list of the bivalent 
chromatin regions in human embryonic stem cells 
(hESCs) [19–21]. In these three studies, data generated 
following genome-wide chromatin immunoprecipitation 
using antibodies against H3K4me3 or H3K27me3 were 
merged to identify genes carrying both modifications. 
Although all three studies limited their analysis to the 
regions surrounding the transcription start site (TSS), the 
number of identified bivalent promoters greatly varies, 
from 1798 in [20], 2500 in [21] and more than 5500 in 
[19]. Moreover, these three lists show an incomplete and 
limited overlap [22]. This discrepancy can be explained 
by the different experimental approaches (i.e., sequencing 
vs microarray), insufficient sequencing depth [23] and 
the use of relaxed statistical criteria. It could also reflect 
the variability between hESC lines, because each study 
used a different line: H1 [19], hES3 [20] an H9 [21]. 
A more recent study precisely improved the accuracy 
and characterization of bivalent regions in both mouse 
and human genomes by relying on datasets for several 
independent ESC lines [24]. This study provided the 
chromatin signature of all annotated promoters in hESCs 
and identified 4979 of them as being bivalent [24].
However, none of these four studies gave the 
exact genomic coordinates of the bivalent regions nor 
investigated the presence of a bivalent signature genome-
wide.  In addition, the spreadsheet-based files used to 
present the results are not easy to handle for integrative 
analyses using DNA methylation array data.
These observations stress the need to establish an 
annotated list of high-confidence (HC) bivalent regions 
in hESCs that can be easily used by researchers and 
clinicians to investigate the relationship between the 
bivalent chromatin signature in hESCs and methylation 
defects in cancer cells. To this aim, we used publicly 
available ChIP-sequencing datasets of several hESC lines 
to determine and characterize bivalent chromatin regions 
genome-wide. We created annotated lists of HC bivalent, 
H3K4me3-only and H3K27me3-only genomic regions 
and developed a user-friendly approach to integrate 
these chromatin signature features in DNA methylation 
analyses.
RESULTS
Creation of a list of HC bivalent genomic regions 
in hESCs
To establish an exhaustive list of the genomic 
regions marked by H3K4me3, H3K27me3 or both (i.e., 
bivalent) in hESCs, we took advantage of publicly 
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available ChIP-sequencing (ChIP-seq) datasets. In total, 
we collected 11 dataset series (i.e., input; H3K4me3 and 
H3K27me3) each produced by the same laboratory and 
using the same hESC sample (Supplementary Table S1). 
By combining the dataset series for the same hESC line, 
we obtained pairs of input, H3K4me3 and H3K27me3 
ChIP-seq datasets for five hESC lines: HUES48, HUES64, 
HUES6, I3 and H1 (Supplementary Table S2). As the 
sequencing depth is critical for obtaining statistically 
significant results [23], we ensured that each ChIP-seq 
dataset included at least 20 million uniquely mapped reads 
(Supplementary Table S2). For each hESC line, peaks 
were called in the H3K4me3 and H3K27me3 datasets 
using Macs1.4.2. Genome-wide, we identified between 
26 354 and 50 312 peaks for H3K4me3 and between 
56 163 and 92 099 for H3K27me3 (Figure 1A and 
Supplementary Table S3). 
We next isolated regions enriched for both histone 
marks and defined as bivalent domains all regions where 
H3K4me3 and H3K27me3 peaks overlapped for at least 
1Kbp (Figure 1B). The number of bivalent domains 
ranged from 7 756 in I3 cells to 10 266 in HUES6 cells 
(Figure 1C, Supplementary Table S3), giving a merged list 
of 12 402 bivalent domains. This variation between hESC 
lines could be explained by different culture conditions or 
antibodies used for ChIP and also the sequencing depth 
across samples (Supplementary Table S2). Indeed, the 
number of uniquely mapped reads correlated with the 
number of identified peaks (for H3K27me3, Pearson’s 
correlation (r) = 0.86, α < 0.05; for H3K4me3 (r) = 0.85, 
α < 0.05). 
A subset of the identified regions was hESC line-
specific, particularly in HUES6 cells (10% of all identified 
bivalent domains) (Figure 1C, Supplementary Table S3). 
These cell line-specific regions tended to have a weaker 
enrichment for H3K27me3 and, to a lesser extent, for 
H3K4me3 compared with bivalent regions present in 
several cell lines (Figure 1D). By restricting the merged 
list to regions present in all five hESC lines, we obtained 
a list of 5 766 HC bivalent domains present in the hESC 
genome. 
By using the same criteria (i.e., more than 1Kbp 
in size and common to the five hESC lines), we also 
established a list of HC H3K4me3-only (n = 11 966) and 
H3K27me3-only (n = 16 361) regions (Supplementary 
Figure S1). These regions had a median size of about 
2.5Kbp and generally did not exceed 3.5Kbp. H3K27me3-
only regions were larger with a size up to 8.5kbp 
(Supplementary Figure S2A).
The full list of these regions, with their genomic 
coordinates, associated gene and main features, is 
available in Supplementary File S1. In addition, to 
facilitate their customized visualization in their genomic 
context, we produced a file ready for uploading on the 
UCSC genome browser (https://genome.ucsc.edu/) 
(Supplementary File S2). 
Most bivalent regions are localized in CGI-rich 
promoter 
At the genomic level, CGIs clearly discriminated 
H3K27me3-only from H3K4me3-only and bivalent 
regions (Figure 1E, Supplementary Table S4). Specifically, 
71% and 61% of bivalent and H3K4me3-only regions, but 
only 1.5% for H3K27me3-only regions overlapped with 
a promoter-associated CGI (CGI/promoter) region. This 
indicates that most CGI/promoters are not marked by 
H3K27me3 alone. 
By including also regions not associated with CGIs, 
74% of H3K4me3-only and 75% of bivalent regions were 
within a promoter. Conversely, only 24.5% of H3K27me3-
only regions were associated with a promoter and most of 
them lacked CGIs (Figure 1E, Supplementary Figure S2B, 
Supplementary Table S4). 
To determine the gene ontology term enrichment 
of each region type, we filtered for genes with several 
promoters and retained only those with a similar chromatin 
signature at all their marked promoters (Supplementary 
Figure S3). Genes with bivalent promoter regions were 
strongly enriched for cell differentiation pathways 
and development processes. On the other hand, basal 
metabolic processes, cell cycle and repair pathways were 
the main terms associated with genes with H3K4me3-only 
promoters (Figure 1F and Supplementary File S3). 
Our strategy, based on an unbiased genome-wide 
approach also revealed that 26% and 25% of H3K4me3-
only and bivalent regions, respectively, were in intergenic 
and gene body areas (Supplementary Table S4). This 
might reflect the presence of not yet annotated promoter 
regions. Sub-class of enhancers could also account for this 
enrichment. Indeed, using the enhancer lists defined by 
the Fantom5 project we found that 39% (563/1436) of the 
bivalent domains and 30% (1054/3502) of the H3K4me3-
only regions not associated with a promoter were in 
regions defined as enhancers (Supplementary File S1). 
Molecular signature associated to bivalent 
promoter regions
We next aimed to characterize the genomic 
composition and molecular signature of the promoter-
associated regions for each of these 3 categories. 
It has been proposed that CGI/promoters prone to 
be hypermethylated in cancer cells are depleted in 
retroelements at the transcriptional start site (TSS) 
[25]. Overall, we found that the three major classes of 
retrotransposons (LINEs, SINEs and long terminal repeats 
(LTRs)) were depleted at TSS; however, bivalent promoter 
regions showed the greatest depletion, particularly in the 
genomic region directly bordering the TSS (Figure 2A, 
Supplementary Figure S2C).
Using publicly available ChIP-seq data for the H1 
and H9 hESC lines, we investigated the deposition of 22 
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histone modifications (Supplementary Table S5). Some 
marks known to be associated with active promoters or 
enhancer regions, such as H3K27ac and H3K79me1, 
were more specifically found at H3K4me3-only regions. 
Conversely, H3K4me2, H2AZ or H3K9ac marked also 
bivalent regions (Figure 2B, Supplementary Figure S2D). 
However, while H3K4me2 and H2AZ signals intensity 
was comparable at H3K4me3-only and bivalent promoters, 
H3K9ac signal was stronger at H3K4me3-only promoters. 
The poorly characterized H3K23me2 mark was present 
both at H3K4me3-only and bivalent promoters, but its 
mean signal intensity was stronger at bivalent promoters. 
H3K27me3-only regions were depleted for most of the 22 
analyzed modifications, if not all. These findings suggest 
that some “active” marks are strictly enriched at active 
promoters, while others, similarly to H3K4me3, can co-
exist with the repressive H3K27me3 mark in a poised 
configuration. This hypothesis is also supported by the 
observation that only the H3K4me3-only promoters (blue 
in the left histogram of Figure 2C) were associated with 
highly expressed genes in hESCs.
Besides histone modifications, the analysis of 
ChIP-seq data for 59 transcription factors in the hES1 
cell line stressed that differently from H3K4me3-only 
promoters, transcription factor occupancy was low at 
H3K27me3-only promoters in hESCs (Supplementary 
Figure S4, Supplementary Table S6). The transcription 
factor occupancy at bivalent promoters showed shared 
and also specific features, compared with H3K4me3-
only promoters, in agreement with their intermediate 
status  (Figure 2D). As expected, components of the 
PRC2 complex that mediates H3K27me3 deposition were 
enriched at bivalent promoters (EZH2: 92.8% of bivalent 
vs 17.2% of H3K4me3-only promoters: Chi-squared 
test p < 2.2e–16; SUZ12: 59.4% of bivalent vs 12.5% of 
H3K4me3-only promoters: Chi-squared test p < 2.2e–16). 
Both promoter categories were also widely marked by 
the Polymerase II complex (PolII, P300, TBP), including 
the PolII form phosphorylated at Ser5 that correlates 
with transcriptional initiation [26]. Conversely, the 
general transcription factor IIF (GTFIIF1) that promotes 
transcriptional elongation  [27] was mainly restricted to 
H3K4me3-only promoters (25.7% of bivalent vs 65.5% of 
H3K4me3-only: Chi-squared test p < 2.2e–16), suggesting 
that at most bivalent promoters, the loaded PolII complex 
is in a unproductive pre-initiation state.
Figure 1: Genome-wide identification of high-confidence bivalent domains in human ES cells. (A) Number of H3K4me3 
(blue columns) and H3K27me3 (purple columns) peaks in each hESC line. The proportion of peaks wider than 1Kbp is indicated by the 
hatched area within each column. (B) Schematic overview of the strategy used to identify bivalent domains. (C) Number of bivalent 
domains identified in each cell line (total/cell line-specific). In total (merged results from the five hESC lines) 12 402 bivalent domains 
were identified of which 5 766 were present in all five cell lines and were considered as high-confidence bivalent domains. (D) ChIP-seq 
read density of H3K27me3 (purple) and H3K4me3 (blue) for each hESC line in a ± 10Kbp window centered on the peak signal. Upper 
panel: high-confidence (i.e., common to all five lines) bivalents domains. Lower panel; cell type-specific bivalent domains. Color code as in 
1C). (E) Genomic features associated with high-confidence H3K4me3-only, bivalent and H3K27me3-only regions. ChIP-seq read density 
(H3K27me3: purple; H3K4me3: blue) is shown for the H1 cell line (see Supplementary Figure S1 for the other hESC lines). (F) Gene 
ontology terms enriched in H3K27me3-only (purple columns), bivalent (black columns) and H3K4me3-only (blue columns) promoters. 
For each category, the five highest terms are shown. The full list is available in Supplementary File S3. 
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PRC2 and PolII complex occupancy defines 
clusters at bivalent promoters
As PRC2 and PolII complex occupancy can 
vary among bivalent promoters [21, 24], to further 
characterize the signature of bivalent promoters in hESCs, 
we investigated the signal density of EZH2 (a PRC2 
component) and PolII, as well as of a dozen of other 
selected factors among which the TATA-box binding 
protein-associated factor1 (TAF1) and the Transcription 
Factor 12 (TCF-12; also named HEB), a component of 
nodal signaling in hESCs, were discriminating. Indeed, 
based on the signal density of these four factors, we 
could classify HC bivalent promoters in three clusters 
(Figure 3). Moreover, we observed a similar clustering also 
when we considered all HC bivalent regions, regardless of 
their promoter status (Supplementary Figure S5). 
The first cluster included about 17% of bivalent 
promoters (748/4330) and was characterized by a sharp 
and strong signal for PolII and TAF1. Conversely, the 
second cluster (22% of bivalent promoters; 952/4330) 
displayed a strong signal for EZH2, and to a lesser extent, 
for TCF12, whereas PolII and TAF1 were depleted. 
The third and main cluster (60% of bivalent promoters) 
included promoters that were similarly marked by all 
these factors. Consistently, a marked enrichment for 
H3K27me3 and depletion for H3K9ac characterized 
bivalent regions from cluster 2 (Supplementary 
Figure S5). Functional gene enrichment analysis indicated 
that promoters belonging to cluster 2 controlled genes 
enriched in transcription factor activity (p value < 10−109) 
and regulation of transcription (p value < 10−62). Cluster 
3 genes were associated with plasma membrane (p value 
< 10−42). In agreement with their molecular signature, genes 
controlled by bivalent promoters of cluster 1 showed the 
highest expression in hESCs. Conversely, expression of 
cluster 2 genes was low, similarly to that of genes controlled 
by H3K27me3-only promoters (Figure 2C).
Genes with bivalent promoters tend to be 
expressed in a tissue-specific manner
It has been proposed that bivalent promoters poise 
genes for activation or repression. To investigate whether 
genes with bivalent promoters were more likely to be 
differentially expressed upon differentiation, we collected 
RNA sequencing data for 34 tissues and primary cell 
lines (Figure 4A). Most of the genes with H3K4me3-only 
Figure 2: Main molecular signatures associated with high-confidence H3K4me3-only, bivalent and KH3K27me3-only 
regions. (A) Frequency of retroelements at all (gray lines); H3K4me3-only (blue lines); bivalent (black lines) and H3K27me3-only (purple 
lines) promoters (± 4 Kbp from the TSS). (B) Occupancy of histone marks at H3K4me3-only; bivalent and H3K27me3-only promoters 
in H1 and H9 hESC lines. Each line represents one promoter; ChIP-seq read densities for a ± 10Kbp window are centered on the peak 
signal. The associated average counts are shown in the lower panel. (C) Expression level of genes with H3K4me3-only (blue columns), 
bivalent (black columns) or H3K27me3-only (purple columns) promoters in H1 and HUES64 hESC lines (left histogram). The right 
histogram shows the expression level of genes with bivalent promoters belonging to cluster 1, 2 and 3, respectively. (D) Transcription factor 
occupancy at bivalent promoters and in H3K4me3-only promoters.
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promoters showed a strong expression in all analyzed 
tissues/cell lines, whereas most genes with H3K27me3-
only promoters were not expressed. These findings 
suggest that the stem cell expression pattern of these two 
gene categories tend to be maintained also following 
differentiation. Genes associated with bivalent promoters 
showed a more dynamic expression pattern. While most 
of them displayed a low basal expression in hESCs, their 
expression was variable (from silent to highly expressed) 
in the different tissues/cells under study, indicating that 
such genes tend to be expressed or firmly repressed in 
a tissue-specific manner. We also observed variability 
between tissues in the overall trend toward expression 
or repression. For instance, most genes associated 
with bivalent promoters in hESCs were repressed in 
hematopoietic cell lines (e.g., CD4 and CD8 naive, CD4 
memory cells) and highly expressed in brain tissues (e.g., 
fetal brain and hippocampus) (Figure 4B). Stritingly, the 
bivalent promoters of genes that were poorly expressed 
in all analyzed tissues belonged mainly to cluster 2. 
Conversely, cluster 1 and 3 bivalent promoters were more 
often found among highly expressed genes. Genes with 
cluster 1 promoters were the most highly expressed in 
most tissues (Figure 4C). This observation suggests that 
genes associated with PolII-enriched bivalent promoters 
in hESCs are more prone to be highly expressed upon 
differentiation.
Integration of the hESC chromatin signature 
features in customized DNA methylation 
analyses using Illumina arrays
To develop a user-friendly approach to 
integrate these hESC chromatin signature features in 
customized DNA methylation analyses, we created a 
text file (Supplementary File S4) ready for uploading 
onto GenomeStudio, the software dedicated to 
methylation analyses performed with the HM450K and 
MethylationEPIC arrays from Illumina. These arrays are 
widely used in laboratories worldwide and are becoming 
the gold standard for high-throughput DNA methylation 
analyses of human specimens. The HM450K array covers 
482421 CpG sites and allows interrogating 98.9% of 
HC bivalent regions (mean coverage, MC: 10.9 probes 
per region), 88.1% of H3K4me3-only regions (MC: 8.7 
probes/region) and 55.7% of H3K27me3-only regions 
(MC: 2.4 probes/regions). Coverage is higher with the 
EPIC arrays that allow interrogating 863904 CpG sites, 
with 99.5% of HC bivalent regions (MC: 12.4 probes/
region), 93.3% of H3K4me3-only regions (MC: 10.3 
probes /regions) and 73.5% of H3K27me3-only (MC: 3.1 
probes/region) (Supplementary Table S7).
After uploading in GenomeStudio, our text file 
(Supplementary File S4) allows selecting the probes that 
belong to all or a selected bivalent, H3K4me3-only or 
H3K27me3-only region from any loaded HM450K or 
MethylationEPIC dataset. This text file also allows selecting 
probes belonging to one of the three clusters we defined 
for bivalent promoters. In addition, functionalities already 
present in GenomeStudio can be used to filter for probes 
associated with a variety of genomic features [e.g., CGI 
(core, shore, shelf), promoters, intergenic…] in order to 
perform fully customized and detailed analyses (Figure 5A).
By using this text file, we first analyzed the DNA 
methylation pattern at CGIs relative to their chromatin 
signature in hESCs. HM450K data for H1 hESCs were 
downloaded from Encode (see Material and Method 
section). This array covered a total of 21 177 CGIs 
analyzed by nearly 146 000 probes. About 36% of these 
probes were located in H3K4me3-only regions, 26% 
Figure 3: Three clusters of high-confidence bivalent promoters in human ES cells. High-confidence bivalent promoters are 
classified in three clusters based on the extent and density of the EZH2, PolII, TAF1 and TCF-12 signals. Each line represents one promoter; 
ChIP-seq read densities are shown for a ± 5Kbp window centered on the peak signal. 
Oncotarget4116www.impactjournals.com/oncotarget
in bivalent regions and only 1.3% in H3K27me3-only 
regions. This further confirms that most CGIs are not 
marked by H3K27me3 alone. The remaining probes 
(36%) were located in CGIs not marked by any of these 
three chromatin signatures in hESCs (referred as “none-
regions”). In agreement with the unmethylated status 
of most CGIs, most of these probes were unmethylated 
(β value < 0.1). Specifically, 90% and 77% of probes 
located in H3K4me3-only and bivalent regions, 
respectively, and 38.5% of probes in none-regions 
displayed a β value < 0.1. Conversely, probes in 
H3K27me3-only regions were methylated and more than 
65% had a β value > 0.7. However, given the low number 
of probes present in these regions, most of the methylated 
probes were actually in none-regions (Figure 5B). This 
suggests that the subset of methylated CGIs in hESCs is 
depleted in canonical histone modifications (H3K4me3 
and H3K27me3). Concerning the genomic features 
associated with CGIs, unmethylated probes (β value 
< 0.3) were mainly located in CGIs with promoter features, 
regardless of the chromatin signature (none, H3K4me3-
only or bivalent). Conversely, methylated probes that were 
mostly in none- and H3K27me3-only regions, to a lesser 
extent, tended to be present mainly in GCIs located in the 
gene body (Figure 5C). 
Bivalent CGIs associated with genes that are less 
prone to be expressed upon differentiation are 
the main target of aberrant hypermethylation in 
cancer
As a proof of concept, we next evaluated the 
relationship between hESC chromatin signatures and 
DNA methylation in cancer. To this aim, we downloaded 
from the TCGA data portal the HM450K data for eight 
solid tumor types and their matched normal controls (from 
21 matched couples for bladder urothelial carcinoma up 
to 90 matched couples for breast invasive carcinoma) 
(Supplementary Table S8). The overall DNA methylation 
pattern observed in hESCs is maintained in normal 
tissues with the majority of CGIs marked by bivalency 
and H3K4me3-only in hESCs remaining unmethylated 
(Supplementary Figure S6). Compared with normal 
tissues, in tumor samples we detected DNA methylation 
changes at CGIs predominantly in bivalent (black) and 
none-regions (gray), with an overall gain of methylation 
Figure 4: Genes with bivalent promoters in human ES cells are differentially expressed in committed cell lineages. 
(A) Expression level in tissues and primary cell lines of genes with H3K4me3-only (upper panel), bivalent (middle panel) and H3K27me3-
only (lower panel) promoters in hESCs. Expression level (in RPKM) is denoted by the color scale (blue to yellow: −6 to +6 on a log2 
scale). (B) Interquartile range of expression in tissues and primary cell lines of genes with a bivalent promoter in hESCs. The median is 
shown in white. (C) Median expression in tissues and primary cell lines of genes with bivalent promoters (all, black diamonds), bivalent 
promoters belonging to cluster 1 (blue circles), cluster 2 (red triangles) or cluster 3 (green squares). In (B) and (C) gene expression level 
was normalized to the median of the expression of H3K4me3-only promoter-associated genes from the same tissue.
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(increased median value). Conversely H3K4me3-only 
regions (blue) were generally unaffected (unmethylated in 
both tumor and control sample) (Figure 6A). In addition, 
at none-regions, the DNA methylation level distribution 
tended to be more more widely distributed in tumor 
samples than in matched controls (bimodal distribution), 
suggesting that, despite the overall gain of methylation, 
both gain and loss of methylation occur at these regions in 
tumor samples (Figure 6A and not shown). 
We then observed that hypermethylated probes 
(delta β value > 0.25 tumor vs control, FDR < 0.05) were 
greatly enriched at bivalent regions, irrespectively of the 
tumor CIMP status. Indeed, in both CIMP-positive and 
CIMP-negative tumors, most of the hypermethylated 
probes at CGIs were in bivalent regions, particularly in 
those belonging to cluster 2 (Figure 6B and 6C). This 
increased to more than 70% in colon adenocarcinoma 
(COAD in Figure 6B; Supplementary Table S9) (to be 
compared with 26% of “bivalent” probes at CGIs on the 
HM450K array). Conversely, H3K4me3-only regions 
were under-represented. Although they accounted for a 
third of all CGI probes on the array, they represented only 
few percents of the hypermethylated probes in all cancer 
types (Figure 6B; Supplementary Table S9). Finally and 
although less prominent than hypermethylation, we also 
observed hypomethylated probes at CGIs in tumors (delta 
β value < 0.25 tumor vs control, FDR <0.05), mainly in 
none-regions.
We next determined the genomic features associated 
with hypermethylated probes in the eight tumor types 
(Figure 6D). The distribution of hypermethylated probes 
was similar in CIMP-positive and CIMP-negative tumors 
and they were mainly located in promoter regions. This 
distribution mainly reflects that of all probes in HM450K, 
indicating that aberrant hypermethylation is equally 
present at CGIs located in promoter regions and in 
intergenic regions or gene bodies. The only exception was 
the H3K4me3-only regions where a relative depletion of 
hypermethylated probes was observed at promoter regions. 
We then collected publicly available RNA 
sequencing data for healthy liver, lung, breast and colon 
tissues to determine whether the gene transcriptional 
status in healthy tissues can influence the gene CGI/
promoter methylation status in the corresponding tumor. 
Overall, gene expression was significantly lower in 
normal tissues for genes with methylated CGI/promoter 
in the corresponding tumor, regardless of the CIMP status, 
compared with gene with unaltered DNA methylation 
patterns (Figure 6E, Supplementary Figure S7). This 
suggests that promoters of poorly expressed or repressed 
genes in healthy tissues are more likely to be aberrantly 
methylated in tumors.
Figure 5: Integration of the ES cell chromatin signature parameters in DNA methylation analyses. (A) Schematic 
overview of the approach to integrate hESC chromatin signature parameters in HM450K and MethylationEPIC (Illumina) array-based 
DNA methylation analyses. (B) Methylation status of CGIs in H1 hESCs according to their chromatin signature; n, number of probes per 
chromatin signature category. (C) Genomic features associated with unmethylated (β value < 0.3) and methylated (β value > 0.7) probes in 
H1 hESC CGIs according to their chromatin signature.
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Aberrant methylation of homeobox gene 
promoters is a common feature of solid cancers 
Finally, to identify classes of genes that are 
recurrently affected in cancer, we selected probes that were 
hypermethylated in at least five of the eight solid tumor 
types analyzed in this study (4360 probes in CIMP-positive 
tumors and 97 in CIMP-negative tumors that covered 
1596 and 84 promoter regions, respectively) (Figure 7A). 
In agreement with our previous findings, most of these 
promoters were in bivalent regions and they belonged 
mainly to cluster 2 and to a lesser extend to cluster 3 
(Figure 7B). Ontology analyses revealed that homeobox 
genes, including HOX genes, were over-represented 
among the genes with a recurrently hypermethylated 
promoter in CIMP-positive tumors (p value < 10−40) as 
well as in CIMP-negative tumor types (p value < 10−8), 
despite the small number of analyzed genes (Figure 7C). 
This suggests that hypermethylation of homeobox gene 
promoters could constitute a pan-cancer signature.
DISCUSSION
The currently available lists of genomic regions 
marked by bivalent chromatin in hESC lines are limited 
to TSS, are only partially overlapping and are poorly 
informative and not adapted to determine genome-wide 
stem cell chromatin signatures that pre-mark CGIs for 
hypermethylation in cancer cells.
With the objective to facilitate studies on the 
molecular bases and the impact of aberrant DNA 
methylation in cancer cells, we integrated publicly 
available datasets obtained from five independent hESC 
lines to establish annotated lists of HC bivalent (n = 5 766), 
H3K4me3-only (n = 11 966) and H3K27me3-only regions 
(n = 16 361). These numbers are in agreement with a recent 
Figure 6: Bivalent CGIs from cluster 2 are the main target of aberrant hypermethylation in cancer. (A) Violin plots 
of CGI β value for none (gray), bivalent (black), H3K4me3-only (blue) and H3K27me3-only (purple) regions in eight types of solid 
tumors (T) and matched normal (N) tissues. The mean β values are plotted on the y-axis, with the median indicated by a dot in the violin. 
(B) Distribution of hyper- and hypo-methylated probes in tumor and matched control tissues according to their chromatin signatures in 
hESCs (none: gray; bivalent: black; H3K4me3-only: blue; H3K27me3-only: red). For each tumor type, CIMP-positive (+) and CIMP-
negative (−) samples were analyzed separately. As a reference, the distribution of all HM450K probes according to their chromatin 
signatures in hESCs is shown in the upper right corner. (C) Relative distribution of hypermethylated probes at bivalent regions (cluster 
1 to 3). (D) Genomic features associated with hypermethylated probes according to the chromatin signature in hESCs and the CIMP 
status of the analyzed tumor samples (merged for all tumor types). Distribution on the whole HM450K array (all probes) is shown as 
reference. (E) Genes with aberrantly hypermethylated CGI/promoter in colon adenocarcinoma tend to be repressed in healthy colon tissue. 
Boxplot representation of the expression levels measured in healthy colon for genes with unaffected or hypermethylated CGI/promoter 
in CIMP-positive (+) and CIMP-negative (−) colon adenocarcinoma samples (p-value: Mann-Whitney test). BLCA: bladder urothelial 
carcinoma; BRCA: breast invasive carcinoma; COAD: colon adenocarcinoma; HNSC: head-neck squamous cell carcinoma; KIRP: kidney 
renal papillary cell carcinoma; LIHC: liver hepatocellular carcinoma; LUSC: lung squamous cell carcinoma; LUAD: lung adenocarcinoma.
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study that identified 4 979 bivalent domains at promoter 
regions in hESCs [24] (4 374 in our study), of which about 
81% are also present in our list. The lists we produced 
include the genomic coordinates and the main features 
of each region and can be easily used by researchers and 
clinicians. 
A number of features, including enrichment in 
retrotransposons, H3K27me3 read density patterns, 
associated chromatin signatures and functions of the 
associated genes, allow discriminating bivalent regions 
from H3K4me3- and H3K27me3-only regions. This 
indicates that the detected chromatin bivalency is unlikely 
to be the result of a mixed hESC population. In addition, 
the very low expression levels of bivalent region-
associated genes in hESCs (10-fold lower compared with 
H3K4me3-only region-associated genes) and their marked 
propensity to gain aberrant DNA methylation in cancer 
cells are two strong evidences against a mixed population. 
Moreover, while some permissive histone marks, 
such as H3K27ac, are only found associated with 
H3K4me3-only regions, others can be present at both 
bivalent and H3K4me3-only regions. This include, 
as previously documented, the histone variant H2AZ 
[21, 24] and some acetylated histone forms, indicating 
that, similarly to H3K4me3, a subset of active histone 
modifications can co-exist with the repressive H3K27me3 
mark in a poised configuration. Intriguingly, our analysis 
also revealed that H3K23me2, a recently identified new 
heterochromatin mark in C. elegans [28], highly marks 
bivalent regions and, to a lesser extent, H3K4me3-only 
regions. 
Our data further support and extend previous 
findings [19, 24] showing that CGIs in hESCs are 
associated with three main chromatin states: H3K4me3-
only, bivalent and no mark (i.e., no H3K4me3 and/or 
H3K27me3). By contrast, H3K27me3-only regions are 
CGI-depleted. This suggests that different mechanisms 
are involved in H3K27me3 deposition. In the emerging 
model indeed, an unmethylated and transcriptionally 
inactive status at CpG island is sufficient to promote the 
recruitment of the polycomb responsive complex PRC2 
[29–31]. As a result, bivalency is the default signature of 
transcriptionally inactive CGIs.  Recent studies suggest 
that this model could also apply to non-pluripotent stem 
cells [32, 33]. Specifically, during somatic development, 
gain or loss of chromatin bivalency at the key CGIs that 
regulate imprinting, the so-called imprinting control 
regions (ICR), contributes to finely tune imprinted gene 
expression [32] 
Beside this CGI-based recruitment, the genomic 
distribution of H3K27me3-only regions highlights 
the existence of an alternative mechanism. Indeed, 
Figure 7: Hypermethylation of homeobox genes is a pan-cancer signature. (A) Number of hypermethylated probes in eight 
solid cancer types, classified as CIMP-positive (+) and CIMP-negative (−). The number of hypermethylated probes in five to eight cancer 
types and the associated number of genes are indicated on the right. (B) Distribution of hypermethylated probes in five to eight cancer types 
(classified as CIMP+ and CIMP− samples) according to the chromatin signature in hESCs. Their distribution in the whole HM450K array 
is shown as reference (left pie chart). (C) Gene ontology terms enrichment for genes with promoter hypermethylated in at least five cancer 
types (CIMP+ and CIMP− samples).  
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H3K27me3-only regions could also be the secondary result 
of H3K27me3 spreading from CGIs. Our observation that 
the H3K27me3 read density at these regions is low and 
widespread suggests a basal and regional enrichment for 
this mark, supporting this hypothesis (Figure 1E and S1).
In agreement with the canonical model in which 
bivalent promoters in ESCs are poised for activation or 
repression upon development [9, 26], we observed that 
unlike H3K4me3- and H3K27me3-only regions, bivalent 
region-associated genes tend to be expressed in a tissue-
specific manner. Interestingly, the overall trend toward 
gene expression or repression highly varies between 
cell and tissue types, particularly between hematopoietic 
cell lines and brain tissues where genes associated with 
bivalent promoters in hESCs tend to be repressed and 
strongly expressed, respectively. This probably reflects the 
variability and complexity of the developmental pathways 
involved in the commitment and/or maintenance of each 
cell lineage. Strikingly, the propensity for a gene to be 
expressed in somatic tissues appears to be dependent on 
the presence at its promoter of a pre-loaded unproductive 
transcription complex in hESCs. Specifically, bivalent 
promoters associated with high PolII and TAF1 occupancy 
in hESCs (cluster 1 in this study) are more prone to be 
expressed upon development. Promoters in this cluster 
could respond more effectively and efficiently to 
environmental cues and stress conditions. 
A key aspect of our work lies in the development of 
a user-friendly approach to further integrate the stem cell 
chromatin signature features, collected in our annotated 
lists, in the widely used Illumina array-based DNA 
methylation analyses. By this mean, we observed that, as 
expected [34], the vast majority of CGIs are unmethylated 
in hESCs and that the subset of methylated CGIs belong 
almost exclusively to the “none-region” category (i.e., 
depleted in both H3K4me3 and H3K27me3) and are 
mainly localized in intergenic and gene body regions. 
This is in agreement with the observation that these two 
marks are anti-correlated with DNA methylation at CGIs 
in mammalian genomes [10, 35–37]. Specifically, as 
genomic sequences enriched for H3K4me cannot recruit 
the de novo methylation machinery [38–39], this mark is 
instrumental for protecting CGIs from DNA methylation. 
Of note, the “none-region” CGIs show a bimodal 
distribution and those in promoter regions are mainly 
unmethylated. This observation suggests the existence 
of an alternative mechanism to protect CGIs from DNA 
methylation. Further studies should determine whether this 
protection mechanism relies on H3K4me3-independent 
transcriptional activity and/or on H3K4me3/H3K27me3-
independent poised configuration at these CGI/promoters.
In a proof-of-concept study, conducted using data 
from eight solid tumor types, we confirmed that aberrant 
cancer-associated DNA hypermethylation targets mainly 
CGIs that carry a bivalent signature in hESCs. We also 
found that aberrant DNA hypermethylation affects 
specifically CGIs belonging to cluster 2. Consistently, 
we show that promoter hypermethylation of HOX genes, 
which are a paradigm of bivalent region-associated 
genes [9], could constitute a pan-cancer signature. 
Besides chromatin signatures, our results also support 
the hypothesis that CGI/promoters of genes repressed in 
healthy tissues are more prone to DNA methylation in 
cancer cells, indicating that only a subset of genes with 
hypermethylated promoters are misregulated in cancer 
cells (vs normal) and contribute to tumor initiation 
or progression. Our annotated lists can facilitate the 
identification of these “driver” genes by restricting the 
possible candidates to hypermethylated genes that are 
associated with H3K4me3-only and bivalent (cluster 1) 
CGI/promoter regions in hESCs.  We observed that these 
two categories of genes are expressed in most tested 
tissues and, therefore, their aberrant methylation is more 
likely to have a functional impact that could contribute to 
the tumorigenic process.
Our observations also raise the question of whether 
the propensity of some CGI/promoters to be aberrantly 
methylated is a direct consequence of the presence 
of a bivalent signature in hESCs or the result of that a 
subset of genes with bivalent promoter in hESCs tend 
to be transcriptionally silent in most healthy tissue, 
predominantly those belonging to the cluster 2. Both 
mechanisms could be involved; however, we favor a 
model in which the presence of a bivalent signature is a 
key determinant of the instructive program for aberrant 
DNA methylation. This is supported, in part, by our 
finding that bivalent CGI/promoters are the main target 
of aberrant hypermethylation in both CIMP-positive and 
CIMP-negative tumors. Specifically, we propose that 
alterations in the control of the bivalent signature upon 
differentiation, for instance due to defects in factors 
involved in bivalency dynamics, could lead to aberrant 
DNA methylation. Candidate factors include the TET 
methylcytosine dioxygenases [40] and their catalytic 
product, the 5hmC that has recently been shown to mark 
promoter in colon that resist to aberrant DNA methylation 
in cancer [41]. Histone demethylases are also strong 
candidate factors. This hypothesis is sustained by the 
observation that mutations in isocitrate deshydrogenase 
(IDH) that affect histone demethylation [42] are sufficient 
to establish a CIMP-positive status in glioma, the main 
brain tumor type [43]. Similarly, alterations in factors that 
control only a small subset of bivalent CGIs could lead 
to a CIMP-negative status. Importantly, in our model, 
DNA hypermethylation is only one facet of bivalent 
domain deregulation because this could also lead to DNA 
methylation-independent defects. Further integrative 
studies on tumor samples combining DNA methylation, 
histone modifications and transcriptional analyses are 
needed to test this hypothesis.
 Altogether we provide here a relevant and easy-to-
use tool to integrate hESC chromatin signature features in 
Oncotarget4121www.impactjournals.com/oncotarget
DNA methylation studies. In addition to cancer research, 
it can be used in a variety of DNA methylation-based 
customized analyses, for instance the age-associated 
epigenetic drift.
MATERIALS AND METHODS
Creation of high-confidence (HC) lists of bivalent, 
H3K4me3 and HK27me3 regions in hESCs
Chip-sequencing data for input, H3K4me3 and 
H3K27me3 immunoprecipitations, aligned on the hg19 
genome assembly were obtained from the NIH Roadmap 
Epigenomics project (http://www.roadmapepigenomics.
org/) for five different hESC lines (H1, I3, HUES6, 
HUES48 and HUES64). Datasets of experiments using 
the same cell line were combined to reach a minimal 
sequencing depth of 20 million uniquely mapped reads 
per experiment (Supplementary Table S2). They were 
then processed with Macs 1.4.2 using the parameters 
presented in Supplementary Table S2, as recommended in 
[44]. Input controls were used for peak detection. For 
each hESC line, H3K4me3 and H3K27me3 peaks were 
analyzed with an in-house R scripts. HC bivalent regions 
were defined as regions where H3K4me3 and H3K27me3 
peaks overlapped for at least 1Kbp and in all five hESC 
lines. By using the same criteria (i.e., more than 1Kbp 
in size and common to all five hESC lines) and after 
exclusion of regions defined as bivalent in at least one 
hESC line, lists of HC H3K4me3-only and H3K27me3-
only  regions were generated. As the used hESC lines 
were derived either from female or male embryos, sex 
chromosomes were excluded from the analysis.
Annotation of lists of HC regions
All databases and annotations were retrieved for 
analysis with the hg19 genome assembly.  The positions of 
genes, repeated elements and CGIs were downloaded from 
UCSC Gencode Comprehensive V19, RepeatMasker and 
CpG island tracks, respectively.  For each gene, promoter 
regions were defined as TSS±1Kbp. Enhancer positions 
were determined with the human_permissive_enhancers_
phase_1_and_2.bed from the Fantom5 project.  HM450K 
and MethylationEPIC array probe positions were based 
on Illumina annotations extracted with the GenomeStudio 
software from the manifest files HumanMethylation450_1
5017482_v.1.2.bpm and MethylationEPIC_v-1-0_B1.bpm. 
Genomic features were associated with each HC region 
using the R Bioconductor package “GenomicRanges”.
Histone modifications and transcription factors
H1 and H9 hESC ChIP-sequencing data for 22 histone 
marks were obtained from the NIH Roadmap Epigenomics 
project (Supplementary Table S5). Peaks were called with 
Macs 1.4.2, using the parameters given in Supplementary 
Table S5. Histone marks were assigned to an HC region 
only if an overlapping peak was present in both H1 and 
H9 cells. Histone mark signals for heatmaps or plots were 
derived from wig files generated with Macs 1.4.2.
Raw data (SRA) files for 59 transcription factor 
ChIP-seq experiments using H1 cells were downloaded 
from Gene Expression Omnibus (GEO) Datasets 
(Supplementary Table S6). These files were converted 
with fastq-dump.2.4.1 and aligned to the hg19 genome 
assembly with bowtie2 (default parameters). Alignments 
were than processed with Macs 1.4.2 using the parameters 
listed in Supplementary Table S6. For annotation, peaks 
with FDR < 0.05 were intersected with HC regions with 
the R Bioconductor package “GenomicRanges”.
To identify HC bivalent region subtypes, K-means 
clustering was computed for a dozen of candidate 
protein factors. Relevant partitioning was obtained 
for four transcription factors: EZH2 (GSM1003524), 
TAF1 (GSM803450), PolII (GSM803366) and TCF12 
(GSM803427). Each HC bivalent region (± 1Kbp 
window) was defined by values corresponding to the 
global signal (RPM) for each of these four transcription 
factors.  K-means clustering was then computed using 
these four values.
Gene expression data and analysis
RPKM expression matrices for protein-coding 
genes, non-coding RNAs and ribosomal genes of 57 
human samples (tissues and cell lines) were obtained 
from the Roadmap Epigenomics project (http://egg2.
wustl.edu/roadmap/web_portal/). A total of 52 298 genes 
were analyzed. Gene expression was considered only for 
genes showing a unique HC chromatin profile at all their 
marked promoter regions (see Supplementary Figure S3, 
for example). 
To take into account the expression dynamics of 
bivalent region-associated genes in adult tissues, their 
expression was normalized to the median expression of 
H3K4me3-only region-associated genes that was globally 
stable among tissues. 
Functional gene enrichment analyses were 
conducted with the functional annotation tools of 
the DAVID 6.7 bioinformatics resources or with the 
GeneRanker tool of the Genomatix software suite (https://
www.genomatix.de/).
Methylation data and analysis
Methylation data were derived from HM450K 
Illumina array-based studies. Β values for the H1 hESC 
line were obtained from GEO Datasets under the accession 
number GSM999379. HM450K methylation data of 
matched normal and tumor samples were from TCGA 
(http://cancergenome.nih.gov/) for eight cancer types 
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(Supplementary Table S8). These tumor samples were 
classified according to their CIMP status provided by [45]. 
Details on loci defining the CIMP status for each tumor 
type are given in Supplementary Table S10. Differential 
methylation analyses were performed using the limma 
R package, as described in [46]. HM450K probes were 
considered differentially methylated when FDR < 0.05 and 
when the β value difference between tumor and matched 
normal sample was higher than 0.25.
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